SCHEMBL14920199

SCHEMBL14920199

CC(C)(C)OC(=O)NCc1ccc(F)c(Oc2ccc([N+](=O)[O-])cc2)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSPB1 P04792 2/20 0.39
MGLL Q99685 2/20 0.38
MAPT P10636 4/20 0.38
MAPK1 P28482 2/20 0.38
MMP13 P45452 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MYOC Q99972 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 1/20 0.37
RPS6KA1 Q15418 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14920678 0.85 RPS6KA1 (0.39) RPS6KA1
SCHEMBL13172664 0.80 MAPT (0.45) ALDH1A1MEN1KMT2AMAPTMAPK1
SCHEMBL31455922 0.80 MAPT (0.45) ALDH1A1MEN1KMT2AMAPTMAPK1
SCHEMBL14920164 0.78 SMN1; SMN2 (0.43) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL14907666 0.76 MGLL (0.54) ALDH1A1MEN1KMT2AMGLLMAPK1
SCHEMBL372131 0.74 PPARG (0.51) ALDH1A1MAPTMAPK1MMP13CYP2C9
SCHEMBL4610695 0.74 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AMAPTNPC1
SCHEMBL19085509 0.73 RPS6KA1 (0.47) RPS6KA1GAAL3MBTL1
SCHEMBL14920053 0.73 RPS6KA1 (0.42) RPS6KA1GAAL3MBTL1
SCHEMBL29467981 0.73 RPS6KA1 (0.42) RPS6KA1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288040-A1 SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION ASTEX THERAPEUTICS LIMITED (GB) 2014-09-25 US disclosed
EP-2773613-A1 SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION Astex Therapeutics Limited (GB) 2014-09-10 EP disclosed
WO-2013064538-A1 SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION ASTEX THERAPEUTICS LIMITED (GB) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288040-A1 SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION NR1H4, CFH, SLC10A1 ALDH1A1 1940/4885MEN1 2004/4885KMT2A 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.